Treatment Intensification of High-Risk BCR Prostate Cancer

PROSCA & BLADDR 2023

A. Rannikko

ESMO 2023 Insights: "Prognostic Role of Metastatic Site in Patients …

Insights from 2023 ESMO Annual Meeting

E. Yekedüz

Year in Review: EMBARK Study and the Evolving Role of Intensified AD…

Cedars Sinai

S. Freedland

SUO 2023 Insights: "Doublets or Triplets for Patients With mCSPC - S…

Insights from 2023 Society of Urologic Oncology Annual Meeting

B. Maughan

EMUC 2023 Insights: "De-Escalating Strategies in mHSPC - Who, When, …

Insights from 2023 European Multidisciplinary Congress on Urological Cancers

B. Tombal

ESMO 2023 Insights: "Real-World OS With Enzalutamide & Abiraterone A…

Insights from 2023 ESMO Annual Meeting

D. George

Therapeutic Approach in mCSPC: Doublets, Triplets, and Patient Selec…

Joshua Lang

ESMO 2023 Insights: "The BonEnza Study - Changes in Bone Mineral Den…

Insights from 2023 ESMO Annual Meeting

A. Dalla Volta

Case-Based Clinical Updates in Prostate Cancer: 77 y/o Practicing Ph…

Total Health

J. Zhang, J. Chadha, S. Raymond

Treatment Landscape of mHSPC: Doublet or Triplet

International Urology Cancer Summit - IUCS

N. Agarwal

Assessment and Decision Tools for Balancing Survival and Quality of …

Insights from 2023 ASCO® Annual Meeting

E. Kessler

Post-Hoc Analyses of Phase 3 ARCHES Trial: OS in Patients With mHSPC…

Yale Cancer Center

D. Petrylak

30 Years Perspective on Advanced Prostate Cancer: Using Biology & Pe…

Houston Methodist

M. Hussain

Cost-Effectiveness Analysis of Seven Treatment Regimens in mHSPC: A …

ASCO GU 2023 Conference Coverage

M. Kohli

Recent Prostate Cancer Updates

Oncology Data Advisor

U. Vaishampayan

ESMO 2023 Insights: "EMBARK Secondary Endpoints - Enzalutamide Monot…

Insights from 2023 ESMO Annual Meeting

U. De Giorgi

ESMO 2023 Insights: "Phase 3 Randomized EMBARK Study - Enzalutamide/…

Insights from 2023 ESMO Annual Meeting

S. Freedland